uniQure NV (FRA:UQ1) Research & Development: €114.90 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UQ1 uniQure NV FRA:UQ1
53 GF Score
Price €35.85
GF Value €5.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV Research & Development?

uniQure NV FRA:UQ1 -1.51% 53 Research & Development is €114.90 Mil as of Mar. 2026. GuruFocus rates FRA:UQ1 with a GF Score™ of 53/100 and a GF Value™ of €5.51 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. uniQure NV's Research & Development for the three months ended in Mar. 2026 was €25.24 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €114.90 Mil.

uniQure NV  (FRA:UQ1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

uniQure NV Research & Development Related Terms

uniQure NV Research & Development Historical Data

* Premium members only.

The historical data trend for uniQure NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV Research & Development Chart

uniQure NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.04 186.53 197.03 137.31 120.14

uniQure NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.43 30.68 29.28 29.71 25.24
FRA:UQ1
53GF Score
uniQure NV FRA:UQ1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

uniQure NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €114.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €114.90 Mil mean?
uniQure NV (FRA:UQ1) has a Research & Development of €114.90 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on uniQure NV and its competitors.
Is uniQure NV's Research & Development too high?
uniQure NV's current Research & Development is €114.90 Mil. Overall, uniQure NV has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Research & Development compare to ALMS and ARQT?
uniQure NV's Research & Development of €114.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on uniQure NV and its competitors. uniQure NV's current Research & Development is €114.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (FRA:UQ1) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.51, compared to a current price of €35.85 — trading 550.6% above its estimated fair value. The current Research & Development is €114.90 Mil. uniQure NV's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For uniQure NV (FRA:UQ1), the current Research & Development is €114.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (FRA:UQ1) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of €35.85 is trading 550.6% above its estimated GF Value™ of €5.51. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for FRA:UQ1:

  • Research & Development: €114.90 Mil
  • GF Value™: €5.51 vs. price of €35.85 (550.6% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the FRA:UQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
53GF Score

Get the complete analysis for FRA:UQ1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.85
Price
€5.51
GF Value